Pulse Health Sciences Launches with a Focus on Supporting Clinical Decision Making.
Match Health Collective announced the launch of Pulse Health Sciences, a new medical education and insights division co-founded by Jackson Choy, who will serve as President. Pulse delivers high-quality, evidence-based, peer-to-peer education designed to help clinicians make better-informed decisions and improve patient outcomes.
Health Technology Insights: Link Cell Therapies Launches to Advance CAR-T Cancer Treatments
Pulse is designed to bring clinicians together to interpret emerging clinical evidence, exchange real-world insights, and apply evolving data to practice in ways that support improved patient care. Its approach is grounded in targeted research and real-world clinical understanding, ensuring programs are relevant, engaging, and impactful for clinicians navigating increasingly complex treatment decisions.
“As the pace of scientific innovation accelerates, clinicians continue to rely on trusted peer dialogue to interpret evidence and apply it meaningfully in practice,” said Kavita Bouknight, Founder and CEO of Match Health Collective. “Pulse reflects our commitment to strengthening that exchange so clinicians can make better-informed decisions that ultimately improve patient outcomes.”
Health Technology Insights: Dilon Technologies Gets FDA Approval for MarginProbe 2 Launch
Jackson Choy, Co-Founder and President of Pulse Health Sciences, brings more than 16 years of leadership experience in life sciences marketing, sales, and commercial strategy. He has held senior commercial roles at leading global biopharmaceutical companies, including AstraZeneca, Pfizer, Gilead, and Johnson & Johnson, where he played critical roles in commercializing multiple cutting-edge therapeutics.
“I’m excited to lead Pulse at a time when clinicians are navigating increasingly complex data and treatment decisions,” said Jackson Choy, President of Pulse Health Sciences. “By bringing experts together around emerging evidence and real world experience, Pulse works alongside clinicians to translate data into actionable insights that support more personalized treatment approaches, informed decision-making, and improved patient outcomes.”
Health Technology Insights: Sentynl Therapeutics Announces FDA Acceptance of CUTX-101 NDA Resubmission
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
Source- PR Newswire
